Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | sodium bile acid cotransporter | 0.0089 | 1 | 1 |
Echinococcus granulosus | sodium bile acid cotransporter | 0.0089 | 1 | 1 |
Onchocerca volvulus | 0.0089 | 1 | 1 | |
Echinococcus granulosus | sodium bile acid cotransporter | 0.0089 | 1 | 1 |
Echinococcus multilocularis | sodium bile acid cotransporter | 0.0089 | 1 | 1 |
Schistosoma mansoni | sodium-bile acid cotransporter related | 0.0089 | 1 | 1 |
Schistosoma mansoni | sodium-bile acid cotransporter related | 0.0089 | 1 | 1 |
Echinococcus granulosus | sodium bile acid cotransporter | 0.0089 | 1 | 1 |
Echinococcus multilocularis | sodium bile acid cotransporter | 0.0089 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0089 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Change (functional) | = 17 % | Tested for analgesic activity, using Tail-Flick test in Mice at the dose of 0.1 ug/mouse administered icv after 60 min. | ChEMBL. | 3625710 |
Change (functional) | = 17 % | Tested for analgesic activity, using Tail-Flick test in Mice at the dose of 0.1 ug/mouse administered icv after 60 min. | ChEMBL. | 3625710 |
Change (functional) | = 19 % | Tested for analgesic activity, using Tail-Flick test in Mice at the dose of 0.1 ug/mouse administered icv after 30 min. | ChEMBL. | 3625710 |
Change (functional) | = 19 % | Tested for analgesic activity, using Tail-Flick test in Mice at the dose of 0.1 ug/mouse administered icv after 30 min. | ChEMBL. | 3625710 |
Change (functional) | = 20 % | Tested for analgesic activity, using Tail-Flick test in Mice at the dose of 0.5 ug/mouse administered icv after 60 min. | ChEMBL. | 3625710 |
Change (functional) | = 20 % | Tested for analgesic activity, using Tail-Flick test in Mice at the dose of 0.5 ug/mouse administered icv after 60 min. | ChEMBL. | 3625710 |
Change (functional) | = 23 % | Tested for analgesic activity, using Tail-Flick test in Mice at the dose of 0.1 ug/mouse administered icv after 5 min. | ChEMBL. | 3625710 |
Change (functional) | = 23 % | Tested for analgesic activity, using Tail-Flick test in Mice at the dose of 0.1 ug/mouse administered icv after 5 min. | ChEMBL. | 3625710 |
Change (functional) | < 33 % | Tested for analgesic activity, using Tail-Flick test in Mice at the dose of 1 ug/mouse administered icv after 60 min. | ChEMBL. | 3625710 |
Change (functional) | < 33 % | Tested for analgesic activity, using Tail-Flick test in Mice at the dose of 1 ug/mouse administered icv after 60 min. | ChEMBL. | 3625710 |
Change (functional) | < 41 % | Tested for analgesic activity, using Tail-Flick test in Mice at the dose of 0.5 ug/mouse administered icv after 30 min. | ChEMBL. | 3625710 |
Change (functional) | < 41 % | Tested for analgesic activity, using Tail-Flick test in Mice at the dose of 0.5 ug/mouse administered icv after 30 min. | ChEMBL. | 3625710 |
Change (functional) | < 63 % | Tested for analgesic activity, using Tail-Flick test in Mice at the dose of 1 ug/mouse administered icv after 30 min. | ChEMBL. | 3625710 |
Change (functional) | < 63 % | Tested for analgesic activity, using Tail-Flick test in Mice at the dose of 1 ug/mouse administered icv after 30 min. | ChEMBL. | 3625710 |
Change (functional) | < 91 % | Tested for analgesic activity, using Tail-Flick test in Mice at the dose of 0.5 ug/mouse administered icv after 5 min. | ChEMBL. | 3625710 |
Change (functional) | < 91 % | Tested for analgesic activity, using Tail-Flick test in Mice at the dose of 0.5 ug/mouse administered icv after 5 min. | ChEMBL. | 3625710 |
Change (functional) | < 130 % | Tested for analgesic activity, using Tail-Flick test in Mice at the dose of 1 ug/mouse administered icv after 5 min. | ChEMBL. | 3625710 |
Change (functional) | < 130 % | Tested for analgesic activity, using Tail-Flick test in Mice at the dose of 1 ug/mouse administered icv after 5 min. | ChEMBL. | 3625710 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.